Cardiac Resynchronization Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Study: Algorithm uses activity, breathing data to predict heart failure events
A non-randomized, double-blind study of 521 patients with heart failure found that the combination of data from minute ventilation and physical activity sensors could predict 34 percent of heart failure events, according to a study published in the European Journal of Heart Failure. “Monitoring early signs of clinical deterioration could allow physicians to adjust medical treatment [...] (Source: mobihealthnews)
Source: mobihealthnews - March 24, 2014 Category: Information Technology Authors: Aditi Pai Tags: Uncategorized activity sensors cardiac resynchronization therapy defibrillation devices European Journal of Heart Failure minute ventilation Physiological Diagnostic Source Type: news

St. Jude Medical's Allure Quadra pacemaker wins FDA OK
The FDA grants pre-market approval to St. Jude Medical's Allure Quadra cardiac resynchronization therapy pacemaker. St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device. Food & Drug Administration (FDA), St. Jude MedicalNews Well, Cardiac Rhythm Management, Pre-Market Approval (PMA), Regulatory/Complianceread more (Source: Mass Device)
Source: Mass Device - March 24, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

Biotronik inks VA deal
Biotronik will provide cardiac rhythm management devices for U.S. military veterans via the Veterans Affairs Administration. Biotronik said it inked a deal to provide cardiac rhythm management devices to the 8 million veterans served by the U.S. Veterans Affairs Dept. The Berlin-based company makes cardiac resynchronization therapy defibrillators and endovascular medical devices. News Well, Cardiac Rhythm Management, Deals Roundupread more (Source: Mass Device)
Source: Mass Device - January 10, 2014 Category: Medical Equipment Authors: Chris Walker Tags: Biotronik U.S. Veteran Affairs Dept. Source Type: news

Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems
Boston Scientific Corporation (NYSE:BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a suite of ACUITY™ X4 quadripolar LV leads and the ACUITY™ PRO lead delivery system. (Source: Medical Design Online News)
Source: Medical Design Online News - December 19, 2013 Category: Medical Equipment Source Type: news

Johns Hopkins Researchers Show How A Modified Pacemaker Strengthens Failing Hearts
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. (Source: Medical Design Online News)
Source: Medical Design Online News - December 10, 2013 Category: Medical Equipment Source Type: news

A modified pacemaker strengthens failing hearts
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. In a new study conducted on animal heart cells described in the Journal of Clinical Investigation, the scientists show that CRT changes these cells so they can contract more forcefully. The researchers also identified an enzyme that mimics this effect of CRT without use of the device. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Johns Hopkins Researchers Show How a Modified Pacemaker Strengthens Failing Hearts - 12/2/13
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - December 2, 2013 Category: Research Source Type: news

Pacing Strategies and Phrenic Nerve Stimulation in CRTPacing Strategies and Phrenic Nerve Stimulation in CRT
Phrenic nerve stimulation frequently limits cardiac resynchronization therapy delivery. What pacing strategies help to prevent the problem? Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New Data Published In EP EuroPace Journal Highlights Differences In CRT-ICD Battery Longevity Across Manufacturers
An independent and first-of-its-kind study from theUniversity of PittsburghMedical Center, published online this week inEP EuroPace,shows there are significant differences in battery longevity between contemporary cardiac resynchronization therapy defibrillator (CRT-D) devices, and that the Boston Scientific Corporation (NYSE:BSX) device has the longest battery life compared to competitive brands. (Source: Medical Design Online News)
Source: Medical Design Online News - October 10, 2013 Category: Medical Equipment Source Type: news

FDA Panel Split on Broader Use of CRT
(MedPage Today) -- GAITHERSBURG, Md. -- An FDA advisory panel was less than definitive in its advice on expanding approved use of cardiac resynchronization therapy (CRT) devices for patients with less severe heart failure. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 9, 2013 Category: Geriatrics Source Type: news

Following FDA Approval Of Ilesto ICD/CRT-D Devices, BIOTRONIK Launches ILESTO DX
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced it has received approval from the Food and Drug Administration (FDA) for its Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices). (Source: Medical Design Online News)
Source: Medical Design Online News - October 7, 2013 Category: Medical Equipment Source Type: news

Self-Adjusting CRT Device Cuts Afib in HF (CME/CE)
ORLANDO (MedPage Today) -- A "smart" cardiac resynchronization therapy with defibrillator (CRT-D) device that automatically adjusts pacing to the patient's needs cut incidence of atrial fibrillation in half in heart failure patients, a post hoc analysis found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 24, 2013 Category: Cardiology Source Type: news

Resynchronization May Be Harmful in Narrow-QRS Heart FailureResynchronization May Be Harmful in Narrow-QRS Heart Failure
QRS width, certainly not echocardiographic dyssynchrony, remains the most effective measure for selecting patients for cardiac resynchronization therapy. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

ESC: CRT No Help, Maybe Harmful with Short QRS (CME/CE)
AMSTERDAM (MedPage Today) -- Cardiac resynchronization therapy (CRT) might harm patients with moderate-to-severe heart failure who have a low QRS duration, a randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 3, 2013 Category: Cardiology Source Type: news

Study Fails To Support Broader Patient Population For Cardiac-Resynchronization Therapy
Cardiac-resynchronization therapy (an advanced feature of pacemakers and ICDs manufactured by Medtronic, Boston Scientific, St. Jude Medical, Biotronik, and Sorin) has been shown to be beneficial in heart failure (HF) patients with a wide QRS interval. These benefits have not been reproduced so far in patients with narrow QRS intervals, though many such patients have ventricular dyssynchrony. Now a new study, presented at the European Society of Cardiology in Amsterdam and published simultaneously in the New England Journal of Medicine, once again has failed to find benefits for CRT in a broader patient populatio...
Source: Forbes.com Healthcare News - September 3, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news